NCT07376265Completed
A Real-world Study to Compare the Effectiveness of Sacubitril/Valsartan Versus ACEi/ARB in HFrEF Patients
Comparative Effectiveness of Sacubitril/Valsartan vs ACEi/ARB in HFrEF Patients: Real Heart PT
Source: ClinicalTrials.gov · Last updated 4 Feb 2026
Brief summary (registry, in English)
This was a retrospective, observational, comparative cohort study using secondary data from electronic health records (EHR) from a local health unit that provides primary, secondary and tertiary care to a resident population in northern Portugal. The study aimed to assess the comparative effectiveness of sacubitril/valsartan (SAC/VAL) versus angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) in patients with heart failure with reduced ejection fraction (HFrEF).
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1249 (actual)
- First submitted
- 22 Jan 2026
- Start date
- 20 Oct 2023
- Primary completion date
- 11 Apr 2024
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Heart failure
- NCT number
- NCT07376265
What you commit to
- Study type: Observational
- Participants enrolled: 1249
- From 20 Oct 2023 to the primary completion date, 11 Apr 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of angioedema or unacceptable side effects during receipt of SAC/VAL, ACEi or ARB
- Severe hepatic impairment, biliary cirrhosis, and cholestasis
Lab values
- Estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m\^2 at SAC/VAL, ACEi or ARB initiation
Other
- Missing sex or date of birth
- Pregnancy
Who the study is looking for
- Left ventricular ejection fraction (LVEF) \< 40%
- Brain natriuretic peptide (BNP) ≥35 pg/mL or N-terminal prohormone of brain natriuretic peptide (NT-proBNP) ≥125 pg/mL
- Had a record in the database in the 365 days prior to the index date
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Novartis Coordinator of this site? Confirm its status | East Hanover | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.